Jacobs Levy Equity Management, Inc Kezar Life Sciences, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.8 - $1.05 $734,095 - $963,499	-917,619 Reduced 94.52%	53,216 $47,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $476,826 - $761,597	662,259 Added 214.62%	970,835 $922,000
Q3 2023 Nov 16, 2023	SELL	$1.08 - $2.54 $318,265 - $748,512	-294,690 Reduced 48.85%	308,576 $367,000
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $671,396 - $889,382	290,648 Added 92.97%	603,266 $1.48 Million
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $670,348 - $1.57 Million	214,169 Added 217.54%	312,618 $978,000
Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $121,946 - $167,939	19,084 Added 24.05%	98,449 $693,000
Q3 2022 Nov 15, 2022	BUY	$7.99 - $10.75 $634,126 - $853,173	79,365 New	79,365 $683,000
Q2 2020 Aug 17, 2020	SELL	$3.6 - $7.75 $54,921 - $118,234	-15,256 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$2.77 - $5.75 $207,323 - $430,364	-74,846 Reduced 83.07%	15,256 $67,000
Q4 2019 Feb 14, 2020	BUY	$2.5 - $4.26 $2,012 - $3,429	805 Added 0.9%	90,102 $361,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $7.58 $267,891 - $676,871	89,297 New	89,297 $293,000

38.2M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $433M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.